Cuenca M - Search Results

1

Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma.

Spaan I, Timmerman LM, Kimman T, Slomp A, Cuenca M, van Nieuwenhuijzen N, Moesbergen LM, Minnema MC, Raymakers RA, Peperzak V. Spaan I, et al. Among authors: cuenca m. Blood Adv. 2021 Jun 22;5(12):2593-2607. doi: 10.1182/bloodadvances.2020003624. Blood Adv. 2021. PMID: 34152396 Free PMC article.

2

Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.

Slomp A, Moesbergen LM, Gong JN, Cuenca M, von dem Borne PA, Sonneveld P, Huang DCS, Minnema MC, Peperzak V. Slomp A, et al. Among authors: cuenca m. Blood Adv. 2019 Dec 23;3(24):4202-4214. doi: 10.1182/bloodadvances.2019000702. Blood Adv. 2019. PMID: 31856269 Free PMC article.

3

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition.

Cuenca M, Van Nieuwenhuijzen N, Moesbergen LM, Bloem A, Minnema MC, Peperzak V. Cuenca M, et al. Haematologica. 2022 Apr 1;107(4):980-983. doi: 10.3324/haematol.2021.279517. Haematologica. 2022. PMID: 34879645 Free PMC article. No abstract available.

4

Advances and Perspectives in the Treatment of B-Cell Malignancies.

Cuenca M, Peperzak V. Cuenca M, et al. Cancers (Basel). 2021 May 8;13(9):2266. doi: 10.3390/cancers13092266. Cancers (Basel). 2021. PMID: 34066840 Free PMC article.

5

CD Maps-Dynamic Profiling of CD1-CD100 Surface Expression on Human Leukocyte and Lymphocyte Subsets.

Kalina T, Fišer K, Pérez-Andrés M, Kuzílková D, Cuenca M, Bartol SJW, Blanco E, Engel P, van Zelm MC. Kalina T, et al. Among authors: cuenca m. Front Immunol. 2019 Oct 23;10:2434. doi: 10.3389/fimmu.2019.02434. eCollection 2019. Front Immunol. 2019. PMID: 31708916 Free PMC article.

6

Ly9 (CD229) Cell-Surface Receptor is Crucial for the Development of Spontaneous Autoantibody Production to Nuclear Antigens.

de Salort J, Cuenca M, Terhorst C, Engel P, Romero X. de Salort J, et al. Among authors: cuenca m. Front Immunol. 2013 Jul 31;4:225. doi: 10.3389/fimmu.2013.00225. eCollection 2013. Front Immunol. 2013. PMID: 23914190 Free PMC article.

7

Ly9 (CD229) Antibody Targeting Depletes Marginal Zone and Germinal Center B Cells in Lymphoid Tissues and Reduces Salivary Gland Inflammation in a Mouse Model of Sjögren's Syndrome.

Puñet-Ortiz J, Sáez Moya M, Cuenca M, Caleiras E, Lazaro A, Engel P. Puñet-Ortiz J, et al. Among authors: cuenca m. Front Immunol. 2018 Nov 16;9:2661. doi: 10.3389/fimmu.2018.02661. eCollection 2018. Front Immunol. 2018. PMID: 30519241 Free PMC article.

8

The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease.

Wang N, Yigit B, van der Poel CE, Cuenca M, Carroll MC, Herzog RW, Engel P, Terhorst C. Wang N, et al. Among authors: cuenca m. Front Immunol. 2019 Apr 17;10:831. doi: 10.3389/fimmu.2019.00831. eCollection 2019. Front Immunol. 2019. PMID: 31057553 Free PMC article.

9

Targeting of Ly9 (CD229) Disrupts Marginal Zone and B1 B Cell Homeostasis and Antibody Responses.

Cuenca M, Romero X, Sintes J, Terhorst C, Engel P. Cuenca M, et al. J Immunol. 2016 Jan 15;196(2):726-37. doi: 10.4049/jimmunol.1501266. Epub 2015 Dec 14. J Immunol. 2016. PMID: 26667173 Free PMC article.

10

CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.

Cuenca M, Sintes J, Lányi Á, Engel P. Cuenca M, et al. Clin Immunol. 2019 Jul;204:43-49. doi: 10.1016/j.clim.2018.10.017. Epub 2018 Oct 26. Clin Immunol. 2019. PMID: 30522694 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters